MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy-Reference-Cited by-同舟云学术

MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy

Published:2018-06-26 Issue:8 Volume:57 Page:420-429
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosomes Cancer

Author:

Samo Ayaz Ali¹,Li Jiuyi¹,Zhou Min²,Sun Yingyu¹,Yang Yuan¹,Zhang Yunqiu¹,Li Jing³,van Duin Mark⁴,Lu Xuzhang⁵,Fan Xiaolong¹^ORCID

Affiliation:

1. School of Life Sciences, Beijing Key Laboratory of Gene Resource and Molecular Development, Laboratory of Neuroscience and Brain Development, Beijing Normal University; Beijing China

2. Department of Hematology; Changzhou No. 3 People's Hospital; Changzhou China

3. School of Life Sciences, Yichuang Biotechnology Industry Research Institute, Beijing Yizhuang Biomedical Park, Daxing District; Beijing China

4. Department of Hematology; Erasmus MC Cancer Center; Rotterdam The Netherlands

5. Department of Hematology; Changzhou No. 2 People's Hospital, The Affiliated Hospital of Nanjing Medical University; Changzhou China

Funder

National Natural Science Foundation of China

The National Key Research and Development Plan

Beijing Cooperative Construction Project

Erik Philip-Sörensen Foundation

High-Level Medical Talents Training Project of Changzhou

Publisher

Wiley

Subject

Cancer Research,Genetics

Reference57 articles.

1. Multiple myeloma;Raab;Lancet.,2009

2. Genetics of multiple myeloma: another heterogeneity level?;Corre;Blood.,2015

3. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma;Bergsagel;Blood.,2005

4. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients;Broyl;Blood.,2010

5. The molecular classification of multiple myeloma;Zhan;Blood.,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines;Frontiers in Oncology;2024-05-10

2. Approach to High-Risk Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

3. Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma;2024-03-05

4. Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma;Clinical Cancer Research;2023-07-14

5. Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real‐world Swedish population receiving modern treatment;European Journal of Haematology;2023-06-04